Abstract
A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor
Highlights
Recent advances in the treatment of multiple myeloma (MM) using newly developed drugs, such as thalidomide, lenalidomide and bortezomib, have improved the survival of the patients with refractory disease
We report the establishment of a novel myeloma cell line, MUM24, which was obtained from the bone marrow of a 64-year-old female patient with immunoglobulin G (IgG) (k)-type MM
The cell surface antigen characteristics for myeloma cells, such as CD38, CD56, Ia (DR) and CD138 were all positive in nearly 100% of the MUM24 cells
Summary
Recent advances in the treatment of multiple myeloma (MM) using newly developed drugs, such as thalidomide, lenalidomide and bortezomib, have improved the survival of the patients with refractory disease. Tumor cells obtained from these patients conferred characteristic chromosomal abnormalities, including deletion of chromosome 13 (del 13), t(4;14) translocation and deletion of chromosome 17, on which tumor suppressor gene TP53 is localized.[1,2,3,4] Here we report the establishment of a novel myeloma cell line, MUM24, which was obtained from the bone marrow of a 64-year-old female patient with immunoglobulin G (IgG) (k)-type MM.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
